Successful azacitidine treatment with increase of regulatory T cells for relapsed acute myeloid leukemia after allogeneic stem cell transplant
- 11 February 2013
- journal article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 54 (9) , 2079-2080
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)Blood, 2012
- 5-Azacytidine as Salvage Treatment in Relapsed Myeloid Tumors after Allogeneic Bone Marrow TransplantationTransplantation and Cellular Therapy, 2011
- Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation settingBlood, 2010
- 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysisBone Marrow Transplantation, 2009
- Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allograftingBone Marrow Transplantation, 2009
- Donor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working PartyJournal of Clinical Oncology, 2007
- Further Analysis of Trials With Azacitidine in Patients With Myelodysplastic Syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group BJournal of Clinical Oncology, 2006
- Crucial Role of DNA Methylation in Determination of Clonally Distributed Killer Cell Ig-like Receptor Expression Patterns in NK CellsThe Journal of Immunology, 2002